ATE342275T1 - Vorübergehend-immortalisierte zellen zur verwendung in gentherapie - Google Patents

Vorübergehend-immortalisierte zellen zur verwendung in gentherapie

Info

Publication number
ATE342275T1
ATE342275T1 AT00923274T AT00923274T ATE342275T1 AT E342275 T1 ATE342275 T1 AT E342275T1 AT 00923274 T AT00923274 T AT 00923274T AT 00923274 T AT00923274 T AT 00923274T AT E342275 T1 ATE342275 T1 AT E342275T1
Authority
AT
Austria
Prior art keywords
polypeptide
cells
temporarily
gene therapy
immortalized cells
Prior art date
Application number
AT00923274T
Other languages
English (en)
Inventor
E Edward Baetge
Shou Wong
Philippe Dupraz
Bernard Thorens
Original Assignee
Heart Biosystems Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/546,269 external-priority patent/US6730513B1/en
Application filed by Heart Biosystems Gmbh filed Critical Heart Biosystems Gmbh
Application granted granted Critical
Publication of ATE342275T1 publication Critical patent/ATE342275T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00923274T 1999-04-12 2000-04-12 Vorübergehend-immortalisierte zellen zur verwendung in gentherapie ATE342275T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12889399P 1999-04-12 1999-04-12
US09/546,269 US6730513B1 (en) 1999-07-20 2000-04-10 Keratinocyte cultures and uses thereof

Publications (1)

Publication Number Publication Date
ATE342275T1 true ATE342275T1 (de) 2006-11-15

Family

ID=26827053

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00923274T ATE342275T1 (de) 1999-04-12 2000-04-12 Vorübergehend-immortalisierte zellen zur verwendung in gentherapie

Country Status (8)

Country Link
EP (1) EP1175436B1 (de)
JP (1) JP2002541786A (de)
AT (1) ATE342275T1 (de)
AU (1) AU4342900A (de)
CA (1) CA2369884C (de)
DE (1) DE60031260T2 (de)
DK (1) DK1702979T3 (de)
WO (1) WO2000061617A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933089A1 (de) * 1999-07-15 2001-01-18 Max Delbrueck Centrum Mittel zur Gewerbsregeneration
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
WO2001049832A2 (en) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
FR2810046B1 (fr) * 2000-06-07 2004-09-10 Neurotech Procede d'immortalisation conditionnelle de cellules et les constructions proteiques pour sa mise en oeuvre
WO2002048319A1 (en) * 2000-12-14 2002-06-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Telomerase immortalized human liver cell lines
US7521234B2 (en) 2001-03-16 2009-04-21 Naoya Kobayashi Mammalian immortalized liver cell
JP2002300900A (ja) * 2001-04-05 2002-10-15 National Institute Of Advanced Industrial & Technology 腫瘍悪性化因子および腫瘍悪性化を抑制する化合物のスクリーニング方法
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
US20050244969A1 (en) * 2001-10-18 2005-11-03 Jan-Heiner Kupper Transient immortalization
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
US20090214420A1 (en) * 2005-04-01 2009-08-27 Medvet Science Pty. Ltd. Method of Diagnosis and Treatment and Agents Useful for Same
IL296832A (en) * 2005-10-18 2022-11-01 Nat Jewish Health Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
AU2014202016B2 (en) * 2005-10-18 2016-05-19 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
DK3339321T3 (da) 2008-08-28 2021-06-21 Taiga Biotechnologies Inc Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
EP2871233A1 (de) 2013-11-12 2015-05-13 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur Herstellung von biogenen Stoffen
EP3548425B1 (de) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanopartikelformulierungen
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
EP3969041A4 (de) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. Zusammensetzungen und verfahren zur behandlung von t-zell-erschöpfung
CN114525238A (zh) * 2022-02-14 2022-05-24 中国农业科学院兰州兽医研究所 一株牛皮肤成纤维永生化细胞系的建立方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE365808T1 (de) * 1995-07-28 2007-07-15 Marie Curie Cancer Care Transportproteine und deren verwendungen
US6495526B2 (en) * 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
US5770422A (en) * 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
DE19740571C1 (de) * 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
EP1073763A4 (de) * 1998-04-28 2002-08-07 Univ Washington Verfahren zur transduktion von fusionsmolekulen

Also Published As

Publication number Publication date
AU4342900A (en) 2000-11-14
DE60031260T2 (de) 2007-05-03
CA2369884C (en) 2010-01-05
EP1175436A2 (de) 2002-01-30
CA2369884A1 (en) 2000-10-19
DK1702979T3 (da) 2012-09-17
WO2000061617A2 (en) 2000-10-19
EP1175436B1 (de) 2006-10-11
DE60031260D1 (de) 2006-11-23
JP2002541786A (ja) 2002-12-10
WO2000061617A3 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
ATE342275T1 (de) Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
ATA165999A (de) Medium zur protein- und serumfreien kultivierung von zellen
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
ATE297987T1 (de) Bedingte immortalisierung von zellen
CY1107121T1 (el) Ρυθμιση διαφοροποιησης αιματοποιητικων βλαστικων κυτταρων με τη χρηση ανθρωπινων μεσυγχυματικων βλαστικων κυτταρων
SE0201328D0 (sv) Hematopoietic differentiation of human embryonic stem cells
DK1220934T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner med anvendelse af apoptoseinhibitorer
AU2126688A (en) Serum free media for the growth of insect cells and expression of products thereby
IL210618A (en) Cell cultures containing isolated and multiplied human cells other than embryonic and germ cells, pharmaceutical preparations containing them, methods of preparation, and methods for identifying modulators and differentiation factors.
MX9207397A (es) Recipientes para cultivo de celulas que tienen hileras interiores y metodo para cultivar celulas en los mismos.
AU2009201827B2 (en) Nerve regeneration
DK1137808T3 (da) Fremgangsmåde til fremstilling af rekombinante celler
YU217890A (sh) Postupak za dobijanje genetskih konstrukcija za ekspresiju nervnog faktora rasta u eukariotskim ćelijama
ATE348876T1 (de) Verfahren zur vermehrung von natürlichen killerzellen
GB9825096D0 (en) Cells,culture methods and their uses
EP0808364A4 (de) Menschliche pancreas zellinien: entwiklungen und anwendungen
FR2716205B1 (fr) Récepteur galanine, acides nucléiques, cellules transformées et utilisations.
ATE517990T1 (de) Effektive kernumprogrammierung in säugetieren
DE69920749D1 (de) Rekombinante bakterienstämme zur herstellung von natürlichen nucleosiden, sowie von modifizierten analogen davon
AU2003222697A1 (en) Method for preparing tissue constructs
ATE297981T1 (de) Herstellung von vakzinen unter der verwendung von hybrid-zellen
AR024989A1 (es) Medios de transformacion de hongos y uso de los mismos para la produccion de proteinas heterologas.
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
WO2004078915A3 (en) Cell culture
CO4790179A1 (es) Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175436

Country of ref document: EP